Why is Hester Bios falling/rising?

As of 16-Sep, Hester Biosciences Ltd's stock price is currently at 2,062.00, reflecting a rise of 7.0 (0.34%). The stock has shown a trend reversal, gaining after two consecutive days of decline. Despite this recent uptick, the stock has underperformed in the short term, with a 1-week return of -2.21% compared to the Sensex's gain of +1.58%. The stock's performance today is in line with the sector, but it has seen a significant drop in investor participation, with delivery volume falling by 47.18% against the 5-day average. While the company has reported very positive results, including a 145.1% growth in net profit and consistent positive results over the last five quarters, it also faces challenges such as a high Debt to EBITDA ratio and poor long-term growth metrics, which may weigh on investor sentiment.
Broader Market Context: In the context of the broader market, Hester Biosciences has struggled significantly over the past year, with a return of -15.49% compared to the Sensex's slight decline of -0.73%. This stark contrast highlights the company's underperformance relative to the market, despite the overall negative returns of the BSE500, which saw a decline of -2.93% in the last year. The stock's valuation appears expensive with a high enterprise value to capital employed ratio, and the lack of domestic mutual fund investment may indicate a lack of confidence in the stock's price or business fundamentals.